{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xing FF"],"funding":["High Level-Hospital Program, Health Commission of Guangdong Province, China.","Sanming Project of Medicine in Shenzhen"],"pagination":["262"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10967482"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(3)"],"pubmed_abstract":["The rebound characteristics of respiratory infections after lifting pandemic control measures were uncertain. From January to November 2023, patients presenting at a teaching hospital were tested for common respiratory viruses and <i>Mycoplasma pneumoniae</i> using a combination of antigen, nucleic acid amplification, and targeted next-generation sequencing (tNGS) tests. The number and rate of positive tests per month, clinical and microbiological characteristics were analyzed. A rapid rebound of SARS-CoV-2 was followed by a slower rebound of <i>M. pneumoniae,</i> with an interval of 5 months between their peaks. The hospitalization rate was higher, with infections caused by respiratory viruses compared to <i>M. pneumoniae</i>. Though the pediatric hospitalization rate of respiratory viruses (66.1%) was higher than that of <i>M. pneumoniae</i> (34.0%), the 4094 cases of <i>M. pneumoniae</i> within 6 months posed a huge burden on healthcare services. Multivariate analysis revealed that <i>M. pneumoniae</i>-infected adults had more fatigue, comorbidities, and higher serum C-reactive protein, whereas children had a higher incidence of other respiratory pathogens detected by tNGS or pathogen-specific PCR, fever, and were more likely to be female. A total of 85% of <i>M. pneumoniae</i>-positive specimens had mutations detected at the 23rRNA gene, with 99.7% showing A2063G mutation. Days to defervescence were longer in those not treated by effective antibiotics and those requiring a change in antibiotic treatment. A delayed but significant rebound of <i>M. pneumoniae</i> was observed after the complete relaxation of pandemic control measures. No unusual, unexplained, or unresponsive cases of respiratory infections which warrant further investigation were identified."],"journal":["Antibiotics (Basel, Switzerland)"],"pubmed_title":["Post-COVID-19 Pandemic Rebound of Macrolide-Resistant <i>Mycoplasma pneumoniae</i> Infection: A Descriptive Study."],"pmcid":["PMC10967482"],"funding_grant_id":["N/A","SZSM201911014"],"pubmed_authors":["Sridhar S","Lung DC","Deng CW","Chan JF","Cai HJ","Chen JL","Ye HY","Sun LL","Hung IF","Lo SK","Xing FF","Cheng VC","Chiu KH","Su YX","Yuen KY","Rong L"],"additional_accession":[]},"is_claimable":false,"name":"Post-COVID-19 Pandemic Rebound of Macrolide-Resistant <i>Mycoplasma pneumoniae</i> Infection: A Descriptive Study.","description":"The rebound characteristics of respiratory infections after lifting pandemic control measures were uncertain. From January to November 2023, patients presenting at a teaching hospital were tested for common respiratory viruses and <i>Mycoplasma pneumoniae</i> using a combination of antigen, nucleic acid amplification, and targeted next-generation sequencing (tNGS) tests. The number and rate of positive tests per month, clinical and microbiological characteristics were analyzed. A rapid rebound of SARS-CoV-2 was followed by a slower rebound of <i>M. pneumoniae,</i> with an interval of 5 months between their peaks. The hospitalization rate was higher, with infections caused by respiratory viruses compared to <i>M. pneumoniae</i>. Though the pediatric hospitalization rate of respiratory viruses (66.1%) was higher than that of <i>M. pneumoniae</i> (34.0%), the 4094 cases of <i>M. pneumoniae</i> within 6 months posed a huge burden on healthcare services. Multivariate analysis revealed that <i>M. pneumoniae</i>-infected adults had more fatigue, comorbidities, and higher serum C-reactive protein, whereas children had a higher incidence of other respiratory pathogens detected by tNGS or pathogen-specific PCR, fever, and were more likely to be female. A total of 85% of <i>M. pneumoniae</i>-positive specimens had mutations detected at the 23rRNA gene, with 99.7% showing A2063G mutation. Days to defervescence were longer in those not treated by effective antibiotics and those requiring a change in antibiotic treatment. A delayed but significant rebound of <i>M. pneumoniae</i> was observed after the complete relaxation of pandemic control measures. No unusual, unexplained, or unresponsive cases of respiratory infections which warrant further investigation were identified.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-04T23:53:27.635Z","creation":"2025-04-04T23:53:27.635Z"},"accession":"S-EPMC10967482","cross_references":{"pubmed":["38534697"],"doi":["10.3390/antibiotics13030262"]}}